valve

Highlights TCT 2019

TCT 2019 | PORTICO: This vs. Any Other Valve Available in the Market

Courtesy of SBHCI. This work, presented at the TCT 2019 Scientific Sessions, showed the 30-day safety and 1-year efficacy of self-expanding prosthesis Portico compared with all valves approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe aortic stenosis and high surgical risk. Between 2014 and 2019, researchers enrolled 750 patients<a href="https://solaci.org/en/2019/09/30/tct-2019-portico-this-vs-any-other-valve-available-in-the-market/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | SCOPE I: Self-Expanding Valve Acurate Neo Head to Head with Sapien 3

Courtesy of SBHCI. This work, which was presented during the TCT 2019 Scientific Sessions and simultaneously published in the Lancet, randomized patients to the ACURATE Neo prosthesis (n = 373) vs. the SAPIEN 3 (n = 367) in a head-to-head comparison involving 20 European sites. Transfemoral access was used in all patients. The study had a noninferiority design, and its primary<a href="https://solaci.org/en/2019/09/30/tct-2019-scope-i-self-expanding-valve-acurate-neo-head-to-head-with-sapien-3/" title="Read more" >...</a>

Costo efectividad de la reparación endovascular y quirúrgica en aneurismas complejos

Impact of Edge to Edge Transcatheter Tricuspid Valve Repair

Reducing tricuspid regurgitation with transcatheter valve repair is associated to improved liver function, which is often ignored by many cardiologists. This is especially true in cases with deteriorated liver function prior valve repair. Instead, kidney function did not show any changes. Transcatheter tricuspid valve repair seems attractive especially in patients with liver failure. Edge to<a href="https://solaci.org/en/2019/08/27/impact-of-edge-to-edge-transcatheter-tricuspid-valve-repair/" title="Read more" >...</a>

Remodelado miocárdico reverso luego del reemplazo valvular

Loss in Life Expectancy after Surgical Aortic Valve Replacement

This study found after surgical aortic valve replacement (SAVR) patients had shorter life expectancy, compared against the general population. This loss in life expectancy was significant, especially in young patients. These results provide essential information to advice patients before and after SAVR. This is an observational national cohort study to assess long term relative survival<a href="https://solaci.org/en/2019/07/18/loss-in-life-expectancy-after-surgical-aortic-valve-replacement/" title="Read more" >...</a>

Endocarditis y TAVI, una complicación rara pero devastadora

Prosthetic Valve Endocarditis and TAVR: though Rare, Devastating

On the bright side, the incidence of prosthetic valve endocarditis (PVE) post TAVR is not higher than post SAVR, according to this study recently presented at EuroPCR 2019, held in Paris. There is plenty of evidence describing PVE incidence, prognosis, risk factors, etc. after surgical valve replacement surgery (SAVR). However, we know little about the<a href="https://solaci.org/en/2019/06/23/prosthetic-valve-endocarditis-and-tavr-though-rare-devastating/" title="Read more" >...</a>

valve in valve

Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients. The VIVA (Valve in Valve) registry, conducted at 23 sites, was a prospective study designed to systematically collect data from patients with degenerated<a href="https://solaci.org/en/2019/06/18/valve-in-valve-with-self-expanding-prosthesis-what-happens-with-gradients-at-one-year/" title="Read more" >...</a>

valve_in_valve-compressor

Good News at 3 Years for “Valve-in-Valve”

In this new era, the paradigm to treat the whole spectrum of transcatheter aortic valve replacement (TAVR) patients has started to shift beyond risk. However, broadening the spectrum raises the question of durability, which is why any long-term TAVR outcomes in any context are welcome. This specific study studied TAVR durability in the treatment of<a href="https://solaci.org/en/2019/06/03/good-news-at-3-years-for-valve-in-valve/" title="Read more" >...</a>

EuroPCR 2019 | COAPT: la reducción de la insuficiencia mitral está asociada a menos hospitalizaciones y muerte

EuroPCR 2019 | COAPT: Mitral Valve Reduction is Associated to Lower Hospitalization and Death

This new analysis shows the mechanism behind the benefit of using MitraClip and the necessary degree of residual mitral regurgitation (MR) to have an impact. Regardless the intervention type, patients with cardiac failure and secondary mitral regurgitation present lower hospitalization for cardiac failure, all-cause mortality and improved quality of life the lower the MR. MitraClip<a href="https://solaci.org/en/2019/05/23/europcr-2019-coapt-mitral-valve-reduction-is-associated-to-lower-hospitalization-and-death/" title="Read more" >...</a>

EuroPCR 2019 | CHOICE: válvula balón expandible vs autoexpandibles en pacientes de alto riesgo

EuroPCR 2019 | CHOICE: Balloon-Expandable Valves vs. Self-Expanding Valves in High-Risk Patients

The CHOICE trial included 241 patients with severe aortic stenosis and high surgical risk who underwent transcatheter aortic valve replacement (TAVR) using transfemoral access. These patients were randomized to balloon-expandable valve (Edwards Sapien XT) vs. self-expanding valve (Medtronic CoreValve). The endpoints were all-cause mortality, stroke, readmission, valve function parameters as measured through an ultrasound, and<a href="https://solaci.org/en/2019/05/23/europcr-2019-choice-balloon-expandable-valves-vs-self-expanding-valves-in-high-risk-patients/" title="Read more" >...</a>

lotus

Lotus Returns with New Strength and the FDA Approval to Compete with Sapien3 and CoreValve Evolut R

After reports of some serious adverse events with first-generation Lotus, the device was pulled off the market—but it was not meant to be left in oblivion. Now, it is back, renewed and with the approval of the United States Food and Drug Administration (FDA), to compete directly with the two market leaders (Sapien and CoreValve),<a href="https://solaci.org/en/2019/04/29/lotus-returns-with-new-strength-and-the-fda-approval-to-compete-with-sapien3-and-corevalve-evolut-r/" title="Read more" >...</a>

Top